Fleximap selected as finalist for the New Zealand Innovation Awards 2017

12 September 2017

Fleximap Ltd, the spinout company from Auckland Bioengineering Institute’s Gastrointestinal Motility Research Group has recently been selected as a finalist in the Health and Science category for the New Zealand Innovation Awards 2017. The New Zealand Innovation Awards are intended to provide a platform for the acknowledgement and celebration of New Zealand individuals and businesses.

Fleximap was founded with the vision to improve the diagnostic accuracy and therapy for patients who suffer from gastrointestinal motility disorders. Their interdisciplinary team comprises biomedical engineers and clinicians who work together to develop innovative products that aid clinicians caring for patients with gastrointestinal motility disorders. In addition to that, they also develop customised physiological solutions for their commercial and research clients.

The FlexiMap electrophysiological mapping system was submitted for evaluation. This innovative system comprises a series of sterilisable flexible electrode arrays, coupled with custom acquisition hardware (FlexiBox) and an automated analysis package (GEMS). Together, this constitutes the world’s first accurate and reliable solution for quantifying and diagnosing gastric dysrhythmias. This project was supported in part by the MedTech CoRE via the Accelerated Research Translation (ART) Fund.

The entries for the awards were evaluated based on a number of criteria. These included value of the project to the customer, its positive impacts on local and/or global markets, as well as the uniqueness of the project.

The awards ceremony for the winning entries will be held on October 19 – we look forward to hearing the results. Auckland Bioengineering Institute wishes the Gastrointestinal Motility Research Group best of luck!